Literature DB >> 12124341

The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.

Bruce C Turner1, Michelle Ottey, Drazen B Zimonjic, Magdalena Potoczek, Walter W Hauck, Edward Pequignot, Catherine L Keck-Waggoner, Cinzia Sevignani, C Marcelo Aldaz, Peter A McCue, Juan Palazzo, Kay Huebner, Nicholas C Popescu.   

Abstract

In various studies of sporadic breast cancers, 40-70% were strongly positive for fragile histidine triad (Fhit) protein expression, whereas only 18% of BRCA2 mutant breast cancers demonstrated strong Fhit expression, suggesting that the BRCA2 repair function may be necessary to retain intact fragile common chromosome fragile site 3B(FRA3B)/FHITloci. In the current study, 22 breast tumors with deleterious BRCA1 mutations were analyzed for Fhit expression by immunohistochemistry in a case-control matched pair analysis. Loss of Fhit expression was significantly more frequent in the BRCA1 cancers compared with sporadic breast tumors (9% Fhit positive versus 68% Fhit positive), suggesting that the BRCA1 pathway is also important in protecting the FRA3B/FHIT locus from damage. To investigate the relationship between repair gene deficiencies and induction of chromosome fragile sites in vitro, we have analyzed the frequency of aphidicolin induction of chromosome gaps and breaks in PMS2-, BRCA1-, MSH2-, MLH1-, FHIT-, and TP53-deficient cell lines. Each of the repair-deficient cell lines showed elevated expression of chromosome gaps and breaks, consistent with the proposal that proteins involved in mismatch and double-strand break repair are important in maintaining the integrity of common fragile regions. Correspondingly, genes at common fragile sites may sustain elevated levels of DNA damage in cells with deficient DNA repair proteins such as those mutated in several familial cancer syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124341

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.

Authors:  S C L Santos; L R Cavalli; I J Cavalli; R S Lima; B R Haddad; E M S F Ribeiro
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  Common fragile sites are conserved features of human and mouse chromosomes and relate to large active genes.

Authors:  Anne Helmrich; Karen Stout-Weider; Klaus Hermann; Evelin Schrock; Thomas Heiden
Journal:  Genome Res       Date:  2006-09-05       Impact factor: 9.043

Review 3.  Common fragile genes and digestive tract cancers.

Authors:  Tamotsu Kuroki; Yoshitsugu Tajima; Jyunichiro Furui; Takashi Kanematsu
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Molecular biology: DNA fragility put into context.

Authors:  Kay Huebner
Journal:  Nature       Date:  2011-02-03       Impact factor: 49.962

Review 5.  FANCJ at the FORK.

Authors:  Sharon B Cantor; Sumeet Nayak
Journal:  Mutat Res       Date:  2016-02-17       Impact factor: 2.433

6.  Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Authors:  Hidetaka Shibata; Satoshi Miuma; Joshua C Saldivar; Kay Huebner
Journal:  Cancer Sci       Date:  2011-07-21       Impact factor: 6.716

7.  BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function.

Authors:  Martin F Arlt; Bo Xu; Sandra G Durkin; Anne M Casper; Michael B Kastan; Thomas W Glover
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 8.  Fhit tumor suppressor: guardian of the preneoplastic genome.

Authors:  Flavia Pichiorri; Tiziana Palumbo; Sung-Suk Suh; Hiroshi Okamura; Francesco Trapasso; Hideshi Ishii; Kay Huebner; Carlo M Croce
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

9.  Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.

Authors:  Gulnur Guler; Kay Huebner; Cigdem Himmetoglu; Rafael E Jimenez; Stefan Costinean; Stefano Volinia; Robert T Pilarski; Mutlu Hayran; Charles L Shapiro
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

10.  Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair.

Authors:  Sohail Jahid; Jian Sun; Ozkan Gelincik; Pedro Blecua; Winfried Edelmann; Raju Kucherlapati; Kathy Zhou; Maria Jasin; Zeynep H Gümüş; Steven M Lipkin
Journal:  Oncotarget       Date:  2017-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.